Molecular pathways: Estrogen pathway in colorectal cancer

Clinical Cancer Research

Volumn 19, Issue 21, 2013, Pages 5842-5848

  Barzi, Afsaneh ^a   Lenz, Annika Medea ^a   Labonte, Melissa J ^b   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b AZUSA PACIFIC UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; ESTRADIOL; ESTRIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTRONE; ISOFLAVONE DERIVATIVE; PROGESTERONE;

ARTICLE; CANCER CELL; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; COLON CANCER; COLON CARCINOGENESIS; COLORECTAL CANCER; DIET THERAPY; DISEASE COURSE; DRUG MECHANISM; ESTROGEN ACTIVITY; ESTROGEN METABOLISM; FOOD COMPOSITION; FOOD INTAKE; GENETIC RISK; GENETIC VARIABILITY; GENOMICS; HORMONE SUBSTITUTION; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; OBSERVATIONAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RISK REDUCTION; SYMPTOM;

ANIMALS; COLORECTAL NEOPLASMS; ESTROGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROGESTERONE; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84887065892     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0325     Document Type: Article

References (70)

1. Siegel R, Jemal A. Colorectal cancer facts & figures. American Cancer Society; 2011.
2. Hendifar A, Yang D, Lenz F, Lurje G, Pohl A, Lenz C, et al. Gender disparities in metastatic colorectal cancer survival. Clin Cancer Res 2009;15: 6391-7.
3. Fernandez E, Bosetti C, La Vecchia C, Levi F, Fioretti F, Negri E. Sex differences in colorectal cancer mortality in Europe, 1955-1996. Eur J Cancer Prev 2000;9: 99-104.
4. Guo JY, Li X, Browning JD Jr, Rottinghaus GE, Lubahn DB, Constantinou A, et al. Dietary soy isoflavones and estrone protect ovariectomized ERalphaKOand wild-type mice from carcinogen-induced colon cancer. J Nutr 2004;134: 179-82.
5. Smirnoff P, Liel Y, Gnainsky J, Shany S, Schwartz B. The protective effect of estrogen against chemically induced murine colon carcinogenesis is associated with decreased CpG island methylation and increased mRNA and protein expression of the colonic vitamin D receptor. Oncol Res 1999;11: 255-64.
6. Weyant MJ, Carothers AM, Mahmoud NN, Bradlow HL, Remotti H, Bilinski RT, et al. Reciprocal expression of ERalpha and ERbeta is associated with estrogen-mediated modulation of intestinal tumorigenesis. Cancer Res 2001;61: 2547-51.
7. KimEJ, Shin HK, Park JH. Genistein inhibits insulin-like growth factor-I receptor signaling in HT-29 human colon cancer cells: a possible mechanism of the growth inhibitory effect of Genistein. J Med Food 2005;8: 431-8.
8. Qi W, Weber CR, Wasland K, Savkovic SD. Genistein inhibits proliferation of colon cancer cells by attenuating a negative effect of epidermal growth factor on tumor suppressor FOXO3 activity. BMC Cancer 2011;11: 219.
9. Ruh TS, Katzenellenbogen BS, Katzenellenbogen JA, Gorski J. Estrone interaction with the rat uterus: in vitro response and nuclear uptake. Endocrinology 1973;92: 125-34.
10. English MA, Kane KF, Cruickshank N, Langman MJ, Stewart PM, Hewison M. Loss of estrogen inactivation in colonic cancer. J Clin Endocrinol Metab 1999;84: 2080-5.
11. English MA, Stewart PM, Hewison M. Estrogen metabolism and malignancy: analysis of the expression and function of 17beta-hydroxysteroid dehydrogenases in colonic cancer. Mol Cell Endocrinol 2001;171: 53-60.
12. Gustafsson JA. Estrogen receptor beta-a new dimension in estrogen mechanism of action. J Endocrinol 1999;163: 379-83.
13. Deroo BJ, Buensuceso AV. Minireview: estrogen receptor-beta: mechanistic insights from recent studies. Mol Endocrinol 2010;24: 1703-14.
14. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, et al. Mechanisms of estrogen action. Physiol Rev 2001;81: 1535-65.
15. Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999;140: 5566-78.
16. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res 2000;60: 245-8.
17. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997;277: 1508-10.
18. Driggers PH, Segars JH. Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling. Trends Endocrinol Metab 2002;13: 422-7.
19. Martin LA, Farmer I, Johnston SR, Ali S, Dowsett M. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. Endocr Relat Cancer 2005;12 Suppl 1:S75-84.
20. Alzamora R, Harvey BJ. Direct binding and activation of protein kinase C isoforms by steroid hormones. Steroids 2008;73: 885-8.
21. Zhang L, Blackman BE, Schonemann MD, Zogovic-Kapsalis T, Pan X, Tagliaferri M, et al. Estrogen receptor beta-selective agonists stimulate calcium oscillations in human and mouse embryonic stem cell-derived neurons. PLoS ONE 2010;5:e11791.
22. Lamprecht SA, Lipkin M. Chemoprevention of colon cancer by calcium, vitamin D, and folate: molecular mechanisms. Nat Rev Cancer 2003;3: 601-14.
23. Aronica SM, Kraus WL, Katzenellenbogen BS. Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMPregulated gene transcription. Proc Natl Acad Sci U S A 1994;91: 8517-21.
24. Kim HP, Lee JY, Jeong JK, Bae SW, Lee HK, Jo I. Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor alpha localized in caveolae. Biochem Biophys Res Commun 1999;263: 257-62.
25. Endoh H, Sasaki H, Maruyama K, TakeyamaK, Waga I, Shimizu T, et al. Rapid activation of MAP kinase by estrogen in the bone cell line. Biochem Biophys Res Commun 1997;235: 99-102.
26. Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM, et al. Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem 2002;277: 24353-60.
27. Treeck O, Lattrich C, Springwald A, Ortmann O. Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells. Breast Cancer Res Treat 2010;120: 557-65.
28. Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML. Functional estrogen receptor beta in colon cancer cells. Biochem Biophys Res Commun 1999;261: 521-7.
29. Arai N, Strom A, Rafter JJ, Gustafsson JA. Estrogen receptor beta mRNA in colon cancer cells: growth effects of estrogen and genistein. Biochem Biophys Res Commun 2000;270: 425-31.
30. Papaxoinis K, Triantafyllou K, Sasco AJ, Nicolopoulou-Stamati P, Ladas SD. Subsite-specific differences of estrogen receptor beta expression in the normal colonic epithelium: implications for carcinogenesis and colorectal cancer epidemiology. Eur J Gastroenterol Hepatol 2010;22: 614-9.
31. Castiglione F, Taddei A, Rossi Degl'Innocenti D, Buccoliero AM, Bechi P, Garbini F, et al. Expression of estrogen receptor beta in colon cancer progression. Diagn Mol Pathol 2008;17: 231-6.
32. Jassam N, Bell SM, Speirs V, Quirke P. Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes' staging. Oncol Rep 2005;14: 17-21.
33. Hartman J, Edvardsson K, Lindberg K, Zhao C, Williams C, Strom A, et al. Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells. Cancer Res 2009;69: 6100-6.
34. Giroux V, Lemay F, Bernatchez G, Robitaille Y, Carrier JC. Estrogen receptor beta deficiency enhances small intestinal tumorigenesis in ApcMin/+mice. Int J Cancer 2008;123: 303-11.
35. Edvardsson K, Strom A, Jonsson P, Gustafsson JA, Williams C. Estrogen receptor beta induces antiinflammatory and antitumorigenic networks in colon cancer cells. Mol Endocrinol 2011;25: 969-79.
36. Kouzmenko AP, Takeyama K, Ito S, Furutani T, Sawatsubashi S, Maki A, et al. Wnt/beta-catenin and estrogen signaling converge in vivo. J Biol Chem 2004;279: 40255-8.
37. Della Torre S, Biserni A, Rando G, Monteleone G, Ciana P, Komm B, et al. The conundrum of estrogen receptor oscillatory activity in the search for an appropriate hormone replacement therapy. Endocrinology 2011;152: 2256-65.
38. Konstantinopoulos PA, Kominea A, Vandoros G, Sykiotis GP, Andricopoulos P, Varakis I, et al. Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer 2003;39: 1251-8.
39. Di Domenico M, Castoria G, Bilancio A, Migliaccio A, Auricchio F. Estradiol activation of human colon carcinoma-derived Caco-2 cell growth. Cancer Res 1996;56: 4516-21.
40. Wu H, Xu L, Chen J, Hu J, Yu S, Hu G, et al. Association of estrogen receptor beta variants and serum levels of estradiol with risk of colorectal cancer: a case control study. BMC Cancer 2012;12: 276.
41. Bielecki A, Roberts J, Mehta R, Raju J. Estrogen receptor-beta mediates the inhibition of DLD-1 human colon adenocarcinomacells by soy isoflavones. Nutr Cancer 2011;63: 139-50.
42. Pintova S, Planoutis K, Planutiene M, Holcombe RF. Genisteininduced reduction of Wnt/beta-catenin pathway activity in colorectal cancer cell lines correlates with inhibition of proliferation and colony growth in soft agar [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research; 2013; Washington, DC. Philladelphia (PA): AACR; 2013.
43. Yan L, Spitznagel EL, Bosland MC. Soy consumption and colorectal cancer risk in humans: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2010;19: 148-58.
44. Xu X, Duncan AM, Wangen KE, Kurzer MS. Soy consumption alters endogenous estrogen metabolism in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2000;9: 781-6.
45. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev 1997;18: 502-19.
46. Faivre E, Skildum A, Pierson-Mullany L, Lange CA. Integration of progesterone receptor mediated rapid signaling and nuclear actions in breast cancer cell models: role of mitogen-activated protein kinases and cell cycle regulators. Steroids 2005;70: 418-26.
47. Takeda A, Leavitt WW. Progestin-induced downregulation of nuclear estrogen receptor in uterine decidual cells: analysis of receptor synthesis and turnover by the density-shift method. Biochem Biophys Res Commun 1986;135: 98-104.
48. Faivre EJ, Lange CA. Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Srcdependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol Cell Biol 2007;27: 466-80.
49. Peterson CM. Estrogen and progesterone receptors: an overview from the year 2000. J Soc Gynecol Investig 2000;7:S3-7.
50. Tanaka Y, Kato K, Mibu R, Uchida S, Asanoma K, Hashimoto K, et al. Medroxyprogesterone acetate inhibits proliferation of colon cancer cell lines by modulating cell cycle-related protein expression. Menopause 2008;15: 442-53.
51. Hartz A, He T, Ross JJ. Risk factors for colon cancer in 150,912 postmenopausal women. Cancer Causes Control 2012;23: 1599-605.
52. Morois S, Fournier A, Clavel-Chapelon F, Mesrine S, Boutron-Ruault MC. Menopausal hormone therapy and risks of colorectal adenomas and cancers in the French E3N prospective cohort: true associations or bias? Eur J Epidemiol 2012;27: 439-52.
53. Hildebrand JS, Jacobs EJ, Campbell PT, McCullough ML, Teras LR, Thun MJ, et al. Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II. Cancer Epidemiol Biomarkers Prev 2009;18: 2835-41.
54. Tannen RL, Weiner MG, Xie D, Barnhart K. Asimulation using data from a primary care practice database closely replicated the Women's Health Initiative trial. J Clin Epidemiol 2007;60: 686-95.
55. Green J, Czanner G, Reeves G, Watson J, Wise L, Roddam A, et al. Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and metaanalysis. Int J Cancer 2012;130: 2387-96.
56. Tannen RL, Weiner MG, Xie D, Barnhart K. Estrogen affects postmenopausal women differently than estrogen plus progestin replacement therapy. Hum Reprod 2007;22: 1769-77.
57. Tsilidis KK, Allen NE, Key TJ, Sanjoaquin MA, Bakken K, Berrino F, et al. Menopausal hormone therapy and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2011;128: 1881-9.
58. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW Jr. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995;87: 517-23.
59. Slattery ML, Anderson K, Samowitz W, Edwards SL, Curtin K, Caan B, et al. Hormone replacement therapy and improved survival among postmenopausal women diagnosed with colon cancer (USA). Cancer Causes Control 1999;10: 467-73.
60. Mandelson MT, Miglioretti D, Newcomb PA, Harrison R, Potter JD. Hormone replacement therapy in relation to survival in women diagnosed with colon cancer. Cancer Causes Control 2003;14: 979-84.
61. Chan JA, Meyerhardt JA, Chan AT, Giovannucci EL, Colditz GA, Fuchs CS. Hormone replacement therapy and survival after colorectal cancer diagnosis. J Clin Oncol 2006;24: 5680-6.
62. Newcomb PA, Chia VM, Hampton JM, Doria-Rose VP, Trentham Dietz A. Hormone therapy in relation to survival from large bowel cancer. Cancer Causes Control 2009;20: 409-16.
63. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004;350: 991-1004.
64. Carling D. The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem Sci 2004;29: 18-24.
65. Newcomb PA, Zheng Y, Chia VM, Morimoto LM, Doria-Rose VP, Templeton A, et al. Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women. Cancer Res 2007;67: 7534-9.
66. Limsui D, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst 2010;102: 1012-22.
67. Schleipen B, Hertrampf T, Fritzemeier KH, Kluxen FM, Lorenz A, Molzberger A, et al. ERbeta-specific agonists and genistein inhibit proliferation and induce apoptosis in the large and small intestine. Carcinogenesis 2011;32: 1675-83.
68. Giroux V, Bernatchez G, Carrier JC. Chemopreventive effect of ERbeta-Selective agonist on intestinal tumorigenesis in Apc(Min/+) mice. Mol Carcinog 2011;50: 359-69.
69. Grady D, Sawaya GF, Johnson KC, Koltun W, Hess R, Vittinghoff E, et al. MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause 2009;16: 458-65.
70. Walsh JM, Cheung AM, Yang D, Litwack S, Grady D. Raloxifene and colorectal cancer. J Womens Health (Larchmt) 2005;14: 299-305.